N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition

Research output: Contribution to journalArticle

Standard

N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition. / Sun, Wei; Parry, Simon; Panico, Maria; Morris, Howard R; Kjellberg, Margareta; Engström, Åke; Dell, Anne; Schedin-Weiss, Sophia.

In: Journal of Biological Chemistry, Vol. 283, No. 27, 2008, p. 18601-18611.

Research output: Contribution to journalArticle

Harvard

Sun, W, Parry, S, Panico, M, Morris, HR, Kjellberg, M, Engström, Å, Dell, A & Schedin-Weiss, S 2008, 'N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition', Journal of Biological Chemistry, vol. 283, no. 27, pp. 18601-18611. https://doi.org/10.1074/jbc.M800608200

APA

Sun, W., Parry, S., Panico, M., Morris, H. R., Kjellberg, M., Engström, Å., Dell, A., & Schedin-Weiss, S. (2008). N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition. Journal of Biological Chemistry, 283(27), 18601-18611. https://doi.org/10.1074/jbc.M800608200

CBE

Sun W, Parry S, Panico M, Morris HR, Kjellberg M, Engström Å, Dell A, Schedin-Weiss S. 2008. N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition. Journal of Biological Chemistry. 283(27):18601-18611. https://doi.org/10.1074/jbc.M800608200

MLA

Vancouver

Author

Sun, Wei ; Parry, Simon ; Panico, Maria ; Morris, Howard R ; Kjellberg, Margareta ; Engström, Åke ; Dell, Anne ; Schedin-Weiss, Sophia. / N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 27. pp. 18601-18611.

RIS

TY - JOUR

T1 - N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition

AU - Sun, Wei

AU - Parry, Simon

AU - Panico, Maria

AU - Morris, Howard R

AU - Kjellberg, Margareta

AU - Engström, Åke

AU - Dell, Anne

AU - Schedin-Weiss, Sophia

PY - 2008

Y1 - 2008

N2 - Protein C inhibitor (PCI) is a serine protease inhibitor, displaying broad protease specificity, found in blood and other tissues. In blood, it is capable of inhibiting both procoagulant and anticoagulant proteases. Mechanisms that provide specificity to PCI remain largely unrevealed. In this study we have for the first time provided a full explanation for the marked size heterogeneity of blood-derived PCI and identified functional differences between naturally occurring PCI variants. The heterogeneity was caused by differences in N-glycan structures, N-glycosylation occupancy, and the presence of a Delta 6-N-cleaved form. Bi-, tri-, and tetra-antennary complex N-glycans were identified. Fucose residues were identified both on the core GlcNAc and as parts of sialyl-Le(a/x) epitopes. Moreover, a glycan with a composition that implied a di-sialyl antenna was observed. PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243. The overall removal of N-glycans affected the maximal heparin- and thrombomodulin-enhanced rates of thrombin inhibition differently in different solution conditions. In contrast, the Delta 6-N-region increased both the heparin- and the thrombomodulin-enhanced rates of thrombin inhibition at all conditions examined. These results thus demonstrate that the N-linked glycans and the N-terminal region of blood-derived PCI in different ways affect the cofactor-enhanced rates of thrombin inhibition and provide information on the mechanisms by which this may be achieved. The findings are medically important, in view of the documented association of PCI with atherosclerotic plaques and the promising effect of PCI on reducing hypercoagulability states.

AB - Protein C inhibitor (PCI) is a serine protease inhibitor, displaying broad protease specificity, found in blood and other tissues. In blood, it is capable of inhibiting both procoagulant and anticoagulant proteases. Mechanisms that provide specificity to PCI remain largely unrevealed. In this study we have for the first time provided a full explanation for the marked size heterogeneity of blood-derived PCI and identified functional differences between naturally occurring PCI variants. The heterogeneity was caused by differences in N-glycan structures, N-glycosylation occupancy, and the presence of a Delta 6-N-cleaved form. Bi-, tri-, and tetra-antennary complex N-glycans were identified. Fucose residues were identified both on the core GlcNAc and as parts of sialyl-Le(a/x) epitopes. Moreover, a glycan with a composition that implied a di-sialyl antenna was observed. PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243. The overall removal of N-glycans affected the maximal heparin- and thrombomodulin-enhanced rates of thrombin inhibition differently in different solution conditions. In contrast, the Delta 6-N-region increased both the heparin- and the thrombomodulin-enhanced rates of thrombin inhibition at all conditions examined. These results thus demonstrate that the N-linked glycans and the N-terminal region of blood-derived PCI in different ways affect the cofactor-enhanced rates of thrombin inhibition and provide information on the mechanisms by which this may be achieved. The findings are medically important, in view of the documented association of PCI with atherosclerotic plaques and the promising effect of PCI on reducing hypercoagulability states.

U2 - 10.1074/jbc.M800608200

DO - 10.1074/jbc.M800608200

M3 - Article

VL - 283

SP - 18601

EP - 18611

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 1083-351X

IS - 27

ER -